BACKGROUND & AIMS:Visceral adipose tissue (VAT) is an important risk factor for the metabolic complications associated with obesity. Therefore, a reduction in VAT is considered an important target of obesity therapy. We evaluated whether reducing VAT mass by surgical removal of the omentum improves insulin sensitivity and metabolic function in obese patients. METHODS: We conducted a 12-month randomized controlled trial to determine whether reducing VAT by omentectomy in 22 obese subjects increased their improvement following Roux-en-Y gastric bypass (RYGB) surgery in hepatic and skeletal muscle sensitivity to insulin study 1. Improvement was assessed by using the hyperinsulinemic-euglycemic clamp technique. We also performed a 3-month, longitudinal, single-arm study to determine whether laparoscopic omentectomy alone, in 7 obese subjects with type 2 diabetes mellitus (T2DM), improved insulin sensitivity study 2. Improvement was assessed by using the Frequently Sampled Intravenous Glucose Tolerance Test. RESULTS: The greater omentum, which weighed 0.82 kg (95% confidence interval: 0.67-0.97), was removed from subjects who had omentectomy in both studies. In study 1, there was an approximate 2-fold increase in muscle insulin sensitivity (relative increase in glucose disposal during insulin infusion) and a 4-fold increase in hepatic insulin sensitivity 12 months after RYGB alone and RYGB plus omentectomy, compared with baseline values (P<.001). There were no significant differences between groups (P>.87) or group x time interactions (P>.36). In study 2, surgery had no effect on insulin sensitivity (P=.844) or use of diabetes medications. CONCLUSIONS: These results demonstrate that decreasing VAT through omentectomy, alone or in combination with RYGB surgery, does not improve metabolic function in obese patients. Copyright (c) 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
RCT Entities:
BACKGROUND & AIMS: Visceral adipose tissue (VAT) is an important risk factor for the metabolic complications associated with obesity. Therefore, a reduction in VAT is considered an important target of obesity therapy. We evaluated whether reducing VAT mass by surgical removal of the omentum improves insulin sensitivity and metabolic function in obesepatients. METHODS: We conducted a 12-month randomized controlled trial to determine whether reducing VAT by omentectomy in 22 obese subjects increased their improvement following Roux-en-Y gastric bypass (RYGB) surgery in hepatic and skeletal muscle sensitivity to insulin study 1. Improvement was assessed by using the hyperinsulinemic-euglycemic clamp technique. We also performed a 3-month, longitudinal, single-arm study to determine whether laparoscopic omentectomy alone, in 7 obese subjects with type 2 diabetes mellitus (T2DM), improved insulin sensitivity study 2. Improvement was assessed by using the Frequently Sampled Intravenous Glucose Tolerance Test. RESULTS: The greater omentum, which weighed 0.82 kg (95% confidence interval: 0.67-0.97), was removed from subjects who had omentectomy in both studies. In study 1, there was an approximate 2-fold increase in muscle insulin sensitivity (relative increase in glucose disposal during insulin infusion) and a 4-fold increase in hepatic insulin sensitivity 12 months after RYGB alone and RYGB plus omentectomy, compared with baseline values (P<.001). There were no significant differences between groups (P>.87) or group x time interactions (P>.36). In study 2, surgery had no effect on insulin sensitivity (P=.844) or use of diabetes medications. CONCLUSIONS: These results demonstrate that decreasing VAT through omentectomy, alone or in combination with RYGB surgery, does not improve metabolic function in obesepatients. Copyright (c) 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
Authors: Caroline S Fox; Joseph M Massaro; Udo Hoffmann; Karla M Pou; Pal Maurovich-Horvat; Chun-Yu Liu; Ramachandran S Vasan; Joanne M Murabito; James B Meigs; L Adrienne Cupples; Ralph B D'Agostino; Christopher J O'Donnell Journal: Circulation Date: 2007-06-18 Impact factor: 29.690
Authors: George A Bray; Kathleen A Jablonski; Wilfred Y Fujimoto; Elizabeth Barrett-Connor; Steven Haffner; Robert L Hanson; James O Hill; Van Hubbard; Andrea Kriska; Elizabeth Stamm; F Xavier Pi-Sunyer Journal: Am J Clin Nutr Date: 2008-05 Impact factor: 7.045
Authors: Vera B Schrauwen-Hinderling; Marco Mensink; Matthijs K C Hesselink; Jean-Pierre Sels; M Eline Kooi; Patrick Schrauwen Journal: J Clin Endocrinol Metab Date: 2008-05-06 Impact factor: 5.958
Authors: C Dirksen; N B Jørgensen; K N Bojsen-Møller; S H Jacobsen; D L Hansen; D Worm; J J Holst; S Madsbad Journal: Diabetologia Date: 2012-04-27 Impact factor: 10.122
Authors: C Robb Flynn; Vance L Albaugh; Robyn A Tamboli; Justin M Gregory; Amma Bosompem; Reem M Sidani; Jason J Winnick Journal: Am J Physiol Gastrointest Liver Physiol Date: 2019-11-11 Impact factor: 4.052
Authors: Mitchel A Kling; John Q Trojanowski; David A Wolk; Virginia M Y Lee; Steven E Arnold Journal: Alzheimers Dement Date: 2012-11-22 Impact factor: 21.566
Authors: Tamara Tchkonia; Thomas Thomou; Yi Zhu; Iordanes Karagiannides; Charalabos Pothoulakis; Michael D Jensen; James L Kirkland Journal: Cell Metab Date: 2013-04-11 Impact factor: 27.287